Citigroup’s Cardiff Oncology CRDF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-28
Closed -$1K 7556
2017
Q4
$1K Hold
28
﹤0.01% 7462
2017
Q3
$1K Buy
+28
New +$1.75K ﹤0.01% 7110

Other funds holding CRDF

Citigroup's CRDF Position: Q2 2026 in Review

Citigroup reduced its Cardiff Oncology (CRDF) stake by 99% in Q2 2026, selling an estimated $63.1K and leaving 501 shares worth $651. The position accounts for ﹤0.01% of the portfolio, ranked #5444.

Citigroup first reported a position in CRDF in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.07M in Q1 2023. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Citigroup held 501 shares of Cardiff Oncology worth $651 as of Q2 2026.
  • Citigroup sold 39,765 Cardiff Oncology shares in Q2 2026, an estimated $63.1K.
  • Cardiff Oncology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5444 holding.
  • Citigroup first reported a position in Cardiff Oncology in Q2 2013 and has held it in 38 quarters since.
  • Citigroup's Cardiff Oncology position peaked at $1.07M in Q1 2023.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.